Added to YB: 2025-03-17
Pitch date: 2025-03-13
MRK [bullish]
Merck & Co., Inc.
+33.99%
current return
Author Info
Jimmy's Journal is an investor and equity analyst sharing research every week. Sign up for the newsletter.
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$298.8B
Pitch Price
$90.20
Price Target
134.00 (+11%)
Dividend
2.81%
EV/EBITDA
11.34
P/E
16.60
EV/Sales
5.15
Sector
Pharmaceuticals
Category
value
Merck & Co. ($MRK) and Keytruda’s Patent Cliff: Risk or Opportunity?
MRK: Keytruda patent expires 2028, 46% of sales. Base case: 40% rev decline, $107 fair value (+14.4%). Bear: 70% decline, $92 (-1%). Bull: No expiry, $130 (+40.5%). Asymmetric upside. Trading 10.5x P/E 2025E. Mitigating via lifecycle management, new indications, acquisitions. EPS impact -4.8% to -10.4% post-expiry.
Read full article (6 min)